Innovent Biologics (HK:1801) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Innovent Biologics has received approval from China’s National Medical Products Administration for its new drug, DOVBLERON, a next-generation ROS1 inhibitor for treating advanced ROS1-positive non-small cell lung cancer. This addition bolsters Innovent’s portfolio and offers a promising option for patients with limited treatment choices. The approval follows successful trials demonstrating DOVBLERON’s efficacy in addressing unmet needs in lung cancer treatment.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.